Skip to main content
SpringerLink
Log in

Management of Symptomatic Intracranial Stenosis

  • Stroke (JF Meschia, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Intracranial atherosclerotic disease is a common cause of stroke worldwide, causing approximately 10 % of strokes in the USA and up to 50 % in Asian populations. Recurrent stroke risks are particularly high in those with a stenosis of 70 % or more and a recent transient ischemic attack or stroke. Warfarin has been associated with higher major hemorrhage rates and no reduction of recurrent stroke compared to aspirin in patients with symptomatic intracranial stenosis. After early trials showed the feasibility of stenting, two randomized trials compared stenting plus medical management to medical management alone in symptomatic intracranial stenosis. Stenting was linked with increased risk and showed no benefit in any subpopulation of patients. Aggressive medical management in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial was associated with half the risk of stroke compared to that in similar patients in a previous symptomatic intracranial stenosis trial after adjustment of confounding characteristics. Aggressive medical management comprises risk factor control, including a target systolic blood pressure <140 mmHg, a low density lipoprotein <70 mg/dL, hemoglobin A1C <7.0 %, and lifestyle management that incorporates exercise, smoking cessation and weight management, and the use of antithrombotics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gorelick P, Wong KS, Bae HJ, Pandey D. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke. 2008;39:2396–9.

    Article  PubMed  Google Scholar 

  2. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 2003;361:107–16.

    Article  CAS  PubMed  Google Scholar 

  3. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis (WASID). N Engl J Med. 2005;352:1305–16.

    Article  CAS  PubMed  Google Scholar 

  4. Kasner SE, Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006;113:555–63.

    Article  PubMed  Google Scholar 

  5. Mazighi M, Tanasescu R, Ducrocq X, Vicaut E, Bracard S, Houdart E, et al. Prospective Study of atherothrombotic intrancranial stenoses, the GESICA study. Neurology. 2006;66:1187–91.

    Article  CAS  PubMed  Google Scholar 

  6. The SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA). Stroke. 2004;35:1388–92.

    Article  Google Scholar 

  7. Zaidat OO, Klucznik R, Alexander MJ, Chaloupka J, Lutsep H, Barnwell S. The NIH registry on use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology. 2008;70:1518–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fiorella DJ, Turk AS, Levy EI, Pride Jr GL, Woo HH, Albuquerque FC. US Wingspan registry 12-month follow-up results. Stroke. 2011;42:1976–81.

    Article  PubMed  Google Scholar 

  9. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial stenosis. N Engl J Med. 2011;365:993–1003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial stenosis (SAMMPRIS): the final results of a randomized trial. Lancet. 2014;383:333–41. This paper provided the final results of a randomized trial comparing stenting with the Wingspan self-expanding stent plus aggressive medical therapy to medical therapy alone in patients with symptomatic high grade intracranial stenosis.

  11. Zaidat OO, Fitzsimmons B-F, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: The VISSIT randomized clinical trial. JAMA. 2015;313:1240–8. This randomized trial compared stenting with the Vitesse balloon-expandable stent plus medical therapy to medical therapy alone in patients with symptomatic high-grade intracranial stenosis.

  12. Fiorella D, Derdeyn CP, Lynn ML, Barnwell SL, Hoh BL, Levy EI, et al. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke. 2012;43:2682–8.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Lutsep HL, Barnwell SL, Larsen DT, Lynn MJ, Hong M, Turan TN, et al. Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. Stroke. 2015;46:775–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lutsep HL, Lynn MJ, Cotsonis GA, Derdeyn CP, Turan TN, Fiorella D, et al. Does the stenting versus aggressive medical therapy trial support stenting for subgroups with intracranial stenosis? Stroke. 2015;46:3282–4.

    Article  PubMed  Google Scholar 

  15. Chaturvedi S, Turan TN, Lynn MJ, Derdeyn CP, Fiorella D, Janis LS, et al. Do patient characteristics explain the differences in outcome between medically treated patients in SAMMPRIS and WASID? Stroke. 2015;46:2562–7.

    Article  PubMed  Google Scholar 

  16. Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology. 2007;69:2063–8.

    Article  CAS  PubMed  Google Scholar 

  17. Chimowitz MI, Derdeyn CP. Endovascular therapy for atherosclerotic intracranial arterial stenosis. JAMA. 2015;313:1219–20.

    Article  CAS  PubMed  Google Scholar 

  18. Turan TN, Lynn ML, Nizam A, Lane B, Egan BM, Le N-A, et al. Rationale, design, and implementation of aggressive risk factor management in the SAMMPRIS trial. Circ Cardiovasc Qual Outcomes. 2012;5:e51–60.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Turan TN, Nizam A, Lynn MJ, Montgomery J, Derdeyn CP, Fiorella D, et al. Relationship between risk factor control and vascular events in the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) trial. Stroke. 2014;45:AWP130 (abstract).

    Article  Google Scholar 

  20. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NS, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded endpoint trial. Lancet Neurol. 2010;9:489–97.

    Article  CAS  PubMed  Google Scholar 

  21. Liu L, Wong KSL, Leng X, Pu Y, Wang Y, Jing X, et al. Dual antiplatelet therapy in stroke and ICAS: subgroup analysis of CHANCE. Neurology. 2015;85:1154–62.

    Article  CAS  PubMed  Google Scholar 

  22. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.

    Article  PubMed  Google Scholar 

  23. Chiu D, Klucznik RP, Turan TN, Lynn MJ, McCane CD, Katz LB, et al. Enrollment volume effect on risk factor control and outcomes in the SAMMPRIS trial. Neurology. 2015;85:2090–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. OHSU Stroke Center and Department of Neurology, Oregon Health & Science University, Portland, OR, USA

    David A. Hoak & Helmi L. Lutsep

  2. OHSU Stroke Center and Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, CR 131, Portland, OR, 97239, USA

    Helmi L. Lutsep

Authors
  1. David A. Hoak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmi L. Lutsep
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helmi L. Lutsep.

Ethics declarations

Conflict of Interest

David A. Hoak and Helmi L. Lutsep declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Stroke

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoak, D.A., Lutsep, H.L. Management of Symptomatic Intracranial Stenosis. Curr Cardiol Rep 18, 83 (2016). https://doi.org/10.1007/s11886-016-0762-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-016-0762-5

Keywords

Search

Navigation